Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 May 1. pii: nov031. [Epub ahead of print] Review.

PMID:
25934816
2.

Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma.

Householder KT, DiPerna DM, Chung EP, Wohlleb GM, Dhruv HD, Berens ME, Sirianni RW.

Int J Pharm. 2015 Feb 20;479(2):374-80. doi: 10.1016/j.ijpharm.2015.01.002. Epub 2015 Jan 3.

3.

Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNF╬▒ in glioblastoma.

Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, Hulme C, Yang W, Lu Z, Aldape K, Sanai N, Rothlin CV, Ghosh S.

Sci Signal. 2014 Aug 12;7(338):ra75. doi: 10.1126/scisignal.2005196.

PMID:
25118327
4.

Targeting adaptive glioblastoma: an overview of proliferation and invasion.

Xie Q, Mittal S, Berens ME.

Neuro Oncol. 2014 Dec;16(12):1575-84. doi: 10.1093/neuonc/nou147. Epub 2014 Jul 30.

PMID:
25082799
5.

Integrated genomic and epigenomic analysis of breast cancer brain metastasis.

Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, DiPerna DM, Paquette KM, Jung S, Nasser S, Wallstrom G, Tembe W, Baker A, Carpten J, Resau J, Ryken T, Sibenaller Z, Petricoin EF, Liotta LA, Ramanathan RK, Berens ME, Tran NL.

PLoS One. 2014 Jan 29;9(1):e85448. doi: 10.1371/journal.pone.0085448. eCollection 2014.

6.

Detection of an atypical teratoid rhabdoid brain tumor gene deletion in circulating blood using next-generation sequencing.

Chakravadhanula M, Tembe W, Legendre C, Carpentieri D, Liang WS, Bussey KJ, Carpten J, Berens ME, Bhardwaj RD.

J Child Neurol. 2014 Sep;29(9):NP81-5. doi: 10.1177/0883073813503904. Epub 2013 Oct 17.

PMID:
24141276
7.

Ligand-dependent EphB1 signaling suppresses glioma invasion and correlates with patient survival.

Teng L, Nakada M, Furuyama N, Sabit H, Furuta T, Hayashi Y, Takino T, Dong Y, Sato H, Sai Y, Miyamoto K, Berens ME, Zhao SG, Hamada J.

Neuro Oncol. 2013 Dec;15(12):1710-20. doi: 10.1093/neuonc/not128. Epub 2013 Oct 11.

8.

Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression.

Fortin Ensign SP, Mathews IT, Symons MH, Berens ME, Tran NL.

Front Oncol. 2013 Oct 4;3:241. doi: 10.3389/fonc.2013.00241. Review.

9.

Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.

Dhruv H, Loftus JC, Narang P, Petit JL, Fameree M, Burton J, Tchegho G, Chow D, Yin H, Al-Abed Y, Berens ME, Tran NL, Meurice N.

J Biol Chem. 2013 Nov 8;288(45):32261-76. doi: 10.1074/jbc.M113.493536. Epub 2013 Sep 20.

10.

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.

Dhruv HD, Whitsett TG, Jameson NM, Patel F, Winkles JA, Berens ME, Tran NL.

Carcinogenesis. 2014 Jan;35(1):218-26. doi: 10.1093/carcin/bgt289. Epub 2013 Aug 23.

11.

Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells.

Dhruv HD, McDonough Winslow WS, Armstrong B, Tuncali S, Eschbacher J, Kislin K, Loftus JC, Tran NL, Berens ME.

PLoS One. 2013 Aug 15;8(8):e72134. doi: 10.1371/journal.pone.0072134. eCollection 2013.

12.

Clinical trials in cellular immunotherapy for brain/CNS tumors.

Badhiwala J, Decker WK, Berens ME, Bhardwaj RD.

Expert Rev Neurother. 2013 Apr;13(4):405-24. doi: 10.1586/ern.13.23. Review.

PMID:
23545055
13.

RTK inhibition: looking for the right pathways toward a miracle.

Xie Q, Vande Woude GF, Berens ME.

Future Oncol. 2012 Nov;8(11):1397-400. doi: 10.2217/fon.12.130.

PMID:
23148613
14.

The small GTPase RhoG mediates glioblastoma cell invasion.

Kwiatkowska A, Didier S, Fortin S, Chuang Y, White T, Berens ME, Rushing E, Eschbacher J, Tran NL, Chan A, Symons M.

Mol Cancer. 2012 Sep 11;11:65. doi: 10.1186/1476-4598-11-65.

15.

Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling.

Creamer MS, Stites EC, Aziz M, Cahill JA, Tan CW, Berens ME, Han H, Bussey KJ, Von Hoff DD, Hlavacek WS, Posner RG.

BMC Syst Biol. 2012 Aug 22;6:107. doi: 10.1186/1752-0509-6-107.

16.

miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2.

Loftus JC, Ross JT, Paquette KM, Paulino VM, Nasser S, Yang Z, Kloss J, Kim S, Berens ME, Tran NL.

PLoS One. 2012;7(6):e39818. doi: 10.1371/journal.pone.0039818. Epub 2012 Jun 22.

17.

Stable gene selection from microarray data via sample weighting.

Yu L, Han Y, Berens ME.

IEEE/ACM Trans Comput Biol Bioinform. 2012 Jan-Feb;9(1):262-72. doi: 10.1109/TCBB.2011.47. Epub 2011 Mar 3.

PMID:
21383420
18.

The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion.

Nakada M, Anderson EM, Demuth T, Nakada S, Reavie LB, Drake KL, Hoelzinger DB, Berens ME.

Int J Cancer. 2010 Mar 1;126(5):1155-65. doi: 10.1002/ijc.24849.

19.

The Pyk2 FERM domain as a target to inhibit glioma migration.

Loftus JC, Yang Z, Tran NL, Kloss J, Viso C, Berens ME, Lipinski CA.

Mol Cancer Ther. 2009 Jun;8(6):1505-14. doi: 10.1158/1535-7163.MCT-08-1055. Epub 2009 Jun 9.

20.

NHERF-1: modulator of glioblastoma cell migration and invasion.

Kislin KL, McDonough WS, Eschbacher JM, Armstrong BA, Berens ME.

Neoplasia. 2009 Apr;11(4):377-87.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk